期刊文献+

血管活性物质与心血管疾病患者的相关性分析

Blood vessel active material and cardiovascular disease patient's relevant analysis
下载PDF
导出
摘要 目的检测冠心病(CHD)和原发性高血压(CH)患者血中NO、CNP、AngⅡ、CGRP和ET的含量,探讨其相关性。方法选择EH患者62例,CHD患者54例为实验组,正常健康者45例为对照组,采用放射免疫法检测血中CNP、AngⅡ、CGRP、ET含量,硝酸还原酶法测定NO含量。结果EH和CHD组分别与对照组比较,CNP、AngⅡ、ET含量明显增高(P<0.01,0.05),NO、CGRP则明显降低(P<0.01,0.01);两组患者CNP、AngⅡ与CGRP之间具有显著负相关性(EH组r=0.556,P<0.01;CHD组r=0.419,P<0.05)。结论检测EH和CHD血中CNP、NO、AngⅡ、CGRP、ET含量变化,对心血管疾病的发病机理研究及其防治具有重要意义。 Objective Examination coronary disease (CHD) and primary hypertension (CH) in patient blood NO, CNP, Ang Ⅱ , CGRP and the ET content, discusses its relevance. Methods Chooses the EH patient 62 examples, the CHD patient 54 examples is an experimental group, the normal healthy persons 45 examples are the control groups, uses the emission immunization to examine in the blood CNP, Ang Ⅱ , CGRP, the ET content, the nitric acid rcductases law determines the NO content. Results EH and the CHD group compares separately with the control group, CNP, AngⅡ , The ET content obvious markup(P 〈0. 01,0. 05) , NO, CGRP obviously reduce( P 〈 0.01,0. 01 ) ; Two group of patient CNP, Ang Ⅱ Has the remarkable inverse correlation with CGRP between( EH group r = 0. 556, P 〈 0. 01 ;CHD group r = 0. 419, P 〈 0. 05 ). Conclusion Examines EH and in the CHD blood CNP, NO, Ang Ⅱ , CGRP, the ET content change, has the important meaning to the cardiovascular disease' s pathogenesis research and the prevention.
作者 王玉亮
出处 《中国实用医药》 2009年第31期9-10,共2页 China Practical Medicine
关键词 血管活性物质 冠心病 原发性高血压 Blood vessel active material Coronary disease Primary hypertension
  • 相关文献

参考文献7

二级参考文献34

  • 1李国红,吕俊升,李秀红.内皮素受体的研究进展[J].中华心血管病杂志,1994,22(4):309-312. 被引量:7
  • 2汤大鸣,洪秀芳,张源明,史政萍.原发性高血压病患者血浆内皮素水平的临床观察[J].放射免疫学杂志,1996,9(1):23-25. 被引量:15
  • 3戴自英.实用内科学(第9版)[M].北京:人民卫生出版社,1993.1345.
  • 4蔡强.神经降压素[J].国外医学消化系统疾病分册,1986,3:129-129.
  • 5陈家津 陈蕾 等.高血压病人血浆中神经降压素含量的变化[J].中国应用生理学杂志,1993,9(2):139-139.
  • 6Scherer EQ, Herzog M, Wangemann P. Endothelin-1-induced vasospasms of spiral modiolar artery are mediated by rho-kinase-induced Ca2+ sensitization of contractile apparatus and reversed by calcitonin gene-related peptide. Stroke, 2002,33: 2965-2973.
  • 7Coleman TP, Tran Q, Roesser JR. Binding of a candidate splice regulator to a calcitonin specific splice enhancer regulates calcitonin/CGRP pre-mRNA splicing. Biol Biophy Acta, 2003,1625: 153- 164.
  • 8Poyner DR, Sexton PM, Marshall I, et al. International union of pharmacology. XXXⅡ. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev, 2002, 54: 233-246.
  • 9Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol, 2001, 41: 851-876.
  • 10Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation, 2000, 102: 2434-2440.

共引文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部